They also had higher AST, ALT and GGT and lower albumin

and platelet count. NASH pts had more often bridging fibrosis STAT inhibitor (48% vs. 1% in NAFL, p<0.001). Central obesity (OR 5.36;95%CI,1.09-26.43), HOMA-IR≥2 (6.24;1.66-23.38) and ALT≥2ULN (3.46;1.50-7.94) independently predicted the diagnosis of NASH by the FLIP algorithm. An HSF was diagnosed by the SAF score in 47 pts (34%). Independent predictors of HSF were: female sex (4.25;1.24-14.54), waist circumference (1.05;1.01-1.09), HOMA-IR≥2 (6.22;1.17-32.90), ALT≥2ULN (10.09;3.22-31.63) and platelet count (0.98;0.97-0.99). Pooling cohort 1 and cohort 2 patients (96% with NASH and 58% with HSF in cohort 2) confirmed these results. Independent predictors of NASH by the FLIP algorithm, in the pooled cohorts, were central obesity (3.94;1.34-11.60), insulin resistance (HOMA-IR≥4 3.01;1.43-6.35) and ALT≥2ULN (10.02; 4.48-22.43); independent predictors of HSF by the SAF score were central obesity (5.51;1.10-27.69), HOMA-IR≥4 (2.73;1.39-5.34), hypertriglyceridemia (2.04;1.06-3.95), ALT≥2ULN (p<0.001; OR, 8.73; 95%CI, 3.50-21.80) and platelet count (p=0.003; OR, 0.99; 95%CI, 0.98-0.99). Conclusion. Pts diagnosed with NASH or HSF by the FLIP algorithm and the SAF score have a distinct clinical this website profile compatible with more advanced obesity-related insulin resistance and biochemical liver injury than those without NASH or with mild histological changes.

These findings demonstrate the clinical relevance of this new histological classification of NAFLD. Disclosures: Dominique G. Larrey – Board Membership: ROCHE GENE, MSD, TIBOTEC/ JANSSEN, ABBOTT, BOEHRINGER, BMS,

GILEAD; Consulting: BAYER, SANOFI, PFIZER, SERVIER-BIG, AEGERION, MMV, BIAL-QUINTILES, TEVA, ORION, NEG-MA-LERADS, ASTELLAS; Grant/Research Support: Roche, Boehringer, BMS, GIL-EAD; Independent Contractor: ABBOTT Lawrence Serfaty – Board Membership: BMS, Gilead; Consulting: Merck; Speaking and Teaching: Roche, Janssen, Merck, Janssen, BMS, Gilead Pascal Lebray – Grant/Research Support: Merck, astellas; Speaking and Teaching: Janssen, MSD, Gilead Thierry Poynard – Advisory Committees or Review Panels: Merck; Speaking and Teaching: BMS; Stock Shareholder: Biopredictive Klaudia M. Traudtner – Employment: Astellas GNA12 Vlad Ratziu – Advisory Committees or Review Panels: GalMed, Abbott, Genfit, Enterome, Gilead; Consulting: Astellas, Axcan, Pfizer, Sanofi-Synthelabo, Genen-tech, Nycomed The following people have nothing to disclose: Fabio Nascimbeni, Pierre Bedossa, Larysa Fedchuk, Raluca Pais, Sven M. Francque, Guruprasad P. Aithal, Mihai Voiculescu Background: Recent studies have shown that vitamin D deficiency (VDD) is associated with obesity and insulin resistance and contributes to increased oxidative stress, systemic inflammation and decreased adiponectin levels. Several studies suggest VDD is prevalent among cases of suspected and biopsy-proven NAFLD in both children and adults.